Every 8-K that Kyntra Bio, Inc. (KYNB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KYNB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYNB filings page.
Kyntra Bio, Inc. (KYNB) amended and restated its Revenue Interest Financing Agreement with NQ Project Phoebus, L.P., cutting the maximum aggregate payments from $125 million to $65 million. This materially reduces royalty-financing obligations by $60 million and eliminates all future true-up payments.
In exchange, Kyntra Bio made a $42.6 million accelerated upfront payment, bringing total payments to NQ Project Phoebus to $50 million, a full return of invested capital. Remaining payments are capped at $15 million, funded by 50% of roxadustat revenue received from Astellas in territories excluding Japan; after that cap, Kyntra Bio retains all subsequent EVRENZO royalties in those territories, and Japan royalties are already unrestricted.
The company also reports that the FibroGen Europe bankruptcy and settlement of related obligations have, together with the amended royalty agreement, reduced future liabilities by approximately $80 million. Cash, cash equivalents, investments, and accounts receivable were $95.7 million as of June 30, 2026, or $53.1 million pro forma for the upfront payment, with a cash runway expected into the fourth quarter of 2027.
Kyntra Bio, Inc. reported second quarter 2026 results showing a sharp swing to profitability driven by a one‑time gain while core revenue declined. Total revenue from continuing operations was $(1.5) million for the quarter, compared with $1.3 million a year earlier, reflecting negative drug product revenue. Net income from continuing operations was $12.0 million, or $2.96 per basic and diluted share, versus a net loss of $13.7 million, or $(3.38) per share, primarily due to a $30.9 million gain on deconsolidation of a subsidiary. As of June 30, 2026, cash, cash equivalents, investments, and accounts receivable totaled $95.7 million, and the company expects this to fund operating plans into 2028.
Operationally, enrollment continues in the Phase 2 monotherapy trial of FG‑3246, an antibody‑drug conjugate targeting CD46 in metastatic castration‑resistant prostate cancer, with an interim analysis planned for the fourth quarter of 2026. The pivotal Phase 3 protocol for roxadustat in anemia related to lower‑risk myelodysplastic syndromes with high transfusion burden has been finalized, with a goal to initiate the registrational study in the fourth quarter of 2026. Additional Phase 3 MATTERHORN data presented at the European Hematology Association Congress 2026 highlighted improvements in transfusion independence for high transfusion burden patients treated with roxadustat.
Kyntra Bio, Inc. reported results from its 2026 annual stockholder meeting held on June 12, 2026. Stockholders elected Class III director Michael Kauffman, M.D., Ph.D., to serve until the 2029 annual meeting, with 1,239,169 votes for, no votes against, 51,081 withheld, and 1,444,428 broker non-votes.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 1,242,005 votes for, 23,606 against, 24,639 abstentions, and 1,444,428 broker non-votes. In addition, they ratified the Audit Committee’s selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 2,712,825 votes for, 14,392 against, and 7,461 abstentions.
Kyntra Bio, Inc. received $4.0 million from AstraZeneca Treasury Limited on June 2, 2026. This payment represents the second and final holdback under their February 20, 2025 share purchase agreement covering the sale of Kyntra’s China operations.
The China business was sold to AstraZeneca on August 29, 2025 for total consideration of approximately $220 million, including $85 million in enterprise value and about $135 million in net cash held in China. Kyntra had previously collected $210 million at closing and a first holdback of $6.0 million plus an additional $0.4 million after final net cash adjustments. With this latest $4.0 million payment, the company has now received all amounts owed under the agreement.
Kyntra Bio reported first quarter 2026 results, showing total revenue from continuing operations of $3.7 million, up from $2.7 million a year earlier, driven mainly by higher drug product revenue. Net loss from continuing operations narrowed to $15.1 million, or $3.74 per share, compared with a $16.8 million loss, or $4.15 per share, in 2025.
The company ended March 31, 2026 with $100.3 million in cash, cash equivalents, investments, and accounts receivable and expects this to fund its operating plans into 2028. Kyntra highlighted steady progress in its pipeline, including an actively enrolling Phase 2 trial of FG-3246 in metastatic castration-resistant prostate cancer with an interim analysis planned for the fourth quarter of 2026, and finalization of a pivotal Phase 3 roxadustat protocol in lower-risk myelodysplastic syndromes ahead of a targeted trial start in the second half of 2026.
Kyntra Bio, Inc. reported receiving a Nasdaq notice on April 2, 2026 that it no longer meets the Nasdaq Global Select Market continued listing requirement of $50 million in total assets and total revenue under Listing Rule 5450(b)(3)(A).
The shortfall arises because revenue of FibroGen International is now presented as held for sale in discontinued operations for 2024 and 2025, and the company also does not meet the alternative shareholders’ equity or market value standards. Kyntra Bio has 45 days, until May 18, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to a 180‑day extension to September 29, 2026 if the plan is accepted.
Kyntra Bio reported fourth quarter and full-year 2025 results and highlighted progress in its oncology and rare disease pipeline. The company is running a Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer, with an interim analysis planned in the second half of 2026, and reported encouraging investigator-sponsored combination data with enzalutamide presented at ASCO meetings.
Kyntra submitted a pivotal Phase 3 protocol for roxadustat in anemia due to lower-risk myelodysplastic syndromes to the FDA and is evaluating whether to advance this program alone or with a partner. Total revenue from continuing operations fell to $6.4 million in 2025 from $29.6 million in 2024, but the net loss from continuing operations narrowed to $58.2 million from $153.1 million, reflecting a restructuring and portfolio shift. The company ended 2025 with $109.4 million in cash, cash equivalents, investments, and accounts receivable and currently expects this to fund operating plans into 2028.